Shortage of Dextrose Monohydrate 70% Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has listed Dextrose Monohydrate 70% Injection as currently in shortage, affecting its availability for various therapeutic uses in the United States.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dextrose Monohydrate 70% Injection.
What's in Shortage
The drug in shortage is Dextrose Monohydrate 70% Injection, with the brand name DEXTROSE. It is available in injection dosage form and falls under therapeutic categories including Endocrinology/Metabolism, Gastroenterology, Other, and Pediatric. The shortage status is current, with the initial posting date of October 11, 2024, and last updated on April 1, 2026.
Which Manufacturers Are Affected
Baxter Healthcare is the manufacturer listed for Dextrose Monohydrate 70% Injection. Their availability status is currently available, with the presentation as Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06). For inquiries, patients or healthcare providers can contact them at 888-229-0001.
Why There's a Shortage
No specific reason for the shortage has been provided in the available data.
What Patients Should Do
Patients who rely on Dextrose Monohydrate 70% Injection should speak with their pharmacist or healthcare provider to check on availability and discuss options. They may also contact the manufacturer directly for more information. Remember, it is important to consult your healthcare provider for any medical concerns—do not make changes to your treatment without professional guidance.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,332 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.